drugset / Trial / NCT04572542
Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate and nab-paclitaxel .
Timeline
- Start
- 2020-01-01
- Primary completion
- 2021-06-01
- Completion
- 2022-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | — |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |